EBD-GROUP
BIO-Europe® 2014 international partnering conference will take place November 3–5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
The conference will kick off with keynote addresses by Andreas Busch, Member, Executive Committee, Head, Global Drug Discovery, Bayer HealthCare; David Loew, Senior VP, Commercial Operations, Europe, Sanofi; and Luciano Rossetti, Executive VP, Head of Global Research and Development, Member of the Pharmaceutical Executive Committee, Merck Serono. The keynote will be followed by their participation in an Opening Plenary Discussion entitled “Biopharma strategy: More focus, more value?” moderated by Jean-François Formela , Partner, Atlas Venture.
A keynote plenary discussion entitled “A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014” will headline the second day of the conference. The keynote plenary will be moderated by Evonne Sepsis , Founder and Managing Director at ESC Advisors and David Stubbs , Founding Partner and Managing Director at Inverness Advisors. The featured panelists are Iain Dukes , Senior VP, Business Development and Licensing at Merck; Shaun Grady , VP, Business Development Operations, AstraZeneca; Adam Keeney , Global Head, External Innovation Operations Strategy, Science Policy and External Innovation, Sanofi; and James Sabry , Senior VP, Global Head of Partnering, Genentech.
“The most compelling aspect of the BIO-Europe keynote plenary topic is sharing reflections on various transformational deals taking place across the industry and unpacking what makes them game-changers,” said Grady. “We’ll discuss what makes a deal within our industry truly transformational, highlighting innovation in the deal structure and the linkage with R&D strategy, assessing commercial potential, and securing and incentivizing the commitment of partners involved. The magic is very often in the details.”
“In thinking about deals at Sanofi, we focus on the opportunities that have the ability to deliver transformational solutions that can significantly benefit the patient,” said Keeney . “Because in the end, deals that transformed the market were those that were open to a paradigm shift in their thinking about disease, and in the way they structured their R&D to remain innovative. I think this bears on our discussion at BIO-Europe.”
Other highlights of the BIO-Europe program include dual track Parallel Panel Discussions. In the Business Development Track, topics range from access to medicines in late-stage clinical trials to funding for EU companies, early market access and sell-side dealmakers. The Spotlight Track features topics ranging from late stage complications in diabetes and next-generation cancer therapies and immunotherapies, to corporate views on personalized immune intervention and advancements in orphan drugs.
In addition, the afternoon will feature Pharmaceutical company presentations from the many pharma companies confirmed to send business development teams to BIO-Europe 2014. They include AbbVie; Alexion Pharmaceuticals; Amgen; AstraZeneca; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Licensing; Bristol-Myers Squibb; Daiichi Sankyo Co., Ltd.; Eli Lilly and Company; Genentech; GlaxoSmithKline; Janssen Pharmaceutical Companies of Johnson & Johnson; Merck Serono; MSD; Novartis; Novo Nordisk; Pfizer; Roche; Sanofi; and Takeda.
At BIO-Europe, companies participate in one-to-one partnering meetings facilitated by EBD Group’s highly reputable partneringONE® platform.
The 2013 edition featured 17,874 one-to-one partnering meetings, an all-time record. Over 3,200 delegates from 1,841 companies representing 56 countries attended. There were 184 company presentations with close to 3,600 licensing opportunities on offer, and 95 exhibitors at the event.
Registration information is available on the BIO-Europe web site for Europe’s largest partnering conference serving the global biotechnology industry.
About BIO-Europe ® 2014:
The 20th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry.
Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
Follow BIO-Europe 2014 on Twitter: twitter.com/ebdgroup (hashtag: No. BEU14). Or log on to the Life Science Partnering discussion forum on partnering360. The Group is your go-to discussion forum for news and topics related to BIO-Europe.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America ™, the fastest growing partnering event in North America
- Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech ™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum ™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141016005083/en/
Contact:
EBD Group
Erin Righetti, +1-760-930-0500
erighetti@ebdgroup.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur® Peripheral Retrievable Stent System30.5.2025 06:08:00 CEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum